Literature DB >> 17072974

Emerging roles of the intestine in control of cholesterol metabolism.

Janine-K Kruit1, Albert K Groen, Theo J van Berkel, Folkert Kuipers.   

Abstract

The liver is considered the major "control center" for maintenance of whole body cholesterol homeostasis. This organ is the main site for de novo cholesterol synthesis, clears cholesterol-containing chylomicron remnants and low density lipoprotein particles from plasma and is the major contributor to high density lipoprotein (HDL; good cholesterol) formation. The liver has a central position in the classical definition of the reverse cholesterol transport pathway by taking up periphery-derived cholesterol from lipoprotein particles followed by conversion into bile acids or its direct secretion into bile for eventual removal via the feces. During the past couple of years, however, an additional important role of the intestine in maintenance of cholesterol homeostasis and regulation of plasma cholesterol levels has become apparent. Firstly, molecular mechanisms of cholesterol absorption have been elucidated and novel pharmacological compounds have been identified that interfere with the process and positively impact plasma cholesterol levels. Secondly, it is now evident that the intestine itself contributes to fecal neutral sterol loss as a cholesterol-secreting organ. Finally, very recent work has unequivocally demonstrated that the intestine contributes significantly to plasma HDL cholesterol levels. Thus, the intestine is a potential target for novel anti-atherosclerotic treatment strategies that, in addition to interference with cholesterol absorption, modulate direct cholesterol excretion and plasma HDL cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072974      PMCID: PMC4100631          DOI: 10.3748/wjg.v12.i40.6429

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  109 in total

1.  Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1.

Authors:  Cheryl L Wellington; Liam R Brunham; Steven Zhou; Roshni R Singaraja; Henk Visscher; Allison Gelfer; Colin Ross; Erick James; Guoqing Liu; Mary T Huber; Yu-Zhou Yang; Robin J Parks; Albert Groen; Jamila Fruchart-Najib; Michael R Hayden
Journal:  J Lipid Res       Date:  2003-05-01       Impact factor: 5.922

2.  Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain.

Authors:  Navdar Sever; Tong Yang; Michael S Brown; Joseph L Goldstein; Russell A DeBose-Boyd
Journal:  Mol Cell       Date:  2003-01       Impact factor: 17.970

3.  Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations.

Authors:  Federica Basso; Lita Freeman; Catherine L Knapper; Alan Remaley; John Stonik; Edward B Neufeld; Terese Tansey; Marcelo J A Amar; Jamila Fruchart-Najib; Nicholas Duverger; Silvia Santamarina-Fojo; H Bryan Brewer
Journal:  J Lipid Res       Date:  2002-11-04       Impact factor: 5.922

4.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Authors:  Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Journal:  Am J Cardiol       Date:  2003-07-15       Impact factor: 2.778

5.  Multiple, independently regulated pathways of cholesterol transport across the intestinal epithelial cells.

Authors:  Jahangir Iqbal; Kamran Anwar; M Mahmood Hussain
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

6.  ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens.

Authors:  Jacob D Mulligan; Matthew T Flowers; Angie Tebon; J James Bitgood; Cheryl Wellington; Michael R Hayden; Alan D Attie
Journal:  J Biol Chem       Date:  2003-01-27       Impact factor: 5.157

7.  Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders.

Authors:  Bethan Jones; Emma L Jones; Stephanie A Bonney; Hetal N Patel; Arjen R Mensenkamp; Sophie Eichenbaum-Voline; Mats Rudling; Urban Myrdal; Grazia Annesi; Sandhia Naik; Nigel Meadows; Aldo Quattrone; Suhail A Islam; Rossitza P Naoumova; Bo Angelin; Recaredo Infante; Emile Levy; Claude C Roy; Paul S Freemont; James Scott; Carol C Shoulders
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

8.  Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8.

Authors:  Liqing Yu; Jennifer York; Klaus von Bergmann; Dieter Lutjohann; Jonathan C Cohen; Helen H Hobbs
Journal:  J Biol Chem       Date:  2003-02-22       Impact factor: 5.157

9.  T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.

Authors:  Naoki Terasaka; Ayano Hiroshima; Tadashi Koieyama; Naoko Ubukata; Yuka Morikawa; Daisuke Nakai; Toshimori Inaba
Journal:  FEBS Lett       Date:  2003-02-11       Impact factor: 4.124

10.  Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist.

Authors:  Emi Kaneko; Morihiro Matsuda; Yukio Yamada; Yoji Tachibana; Iichiro Shimomura; Makoto Makishima
Journal:  J Biol Chem       Date:  2003-07-07       Impact factor: 5.157

View more
  52 in total

1.  A new model system swims into focus: using the zebrafish to visualize intestinal metabolism in vivo.

Authors:  Juliana D Carten; Steven A Farber
Journal:  Clin Lipidol       Date:  2009-08-01

2.  Getting the inside tract: new frontiers in zebrafish digestive system biology.

Authors:  Kirsten C Sadler; John F Rawls; Steven A Farber
Journal:  Zebrafish       Date:  2013-06       Impact factor: 1.985

Review 3.  A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

Review 4.  Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development.

Authors:  Geesje M Dallinga-Thie; Robin P F Dullaart; Arie van Tol
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

5.  Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.

Authors:  François Briand; Morgan Tréguier; Agnès André; Didier Grillot; Marc Issandou; Khadija Ouguerram; Thierry Sulpice
Journal:  J Lipid Res       Date:  2009-10-27       Impact factor: 5.922

Review 6.  Protein mediators of sterol transport across intestinal brush border membrane.

Authors:  J Mark Brown; Liqing Yu
Journal:  Subcell Biochem       Date:  2010

7.  Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression.

Authors:  Ivan Tancevski; Andreas Wehinger; Egon Demetz; Philipp Eller; Kristina Duwensee; Julia Huber; Kathrin Hochegger; Wilfried Schgoer; Catherine Fievet; Frans Stellaard; Mats Rudling; Josef R Patsch; Andreas Ritsch
Journal:  Endocrinology       Date:  2008-04-03       Impact factor: 4.736

8.  Fatty acid- and cholesterol transporter protein expression along the human intestinal tract.

Authors:  Christiaan J Masson; Jogchum Plat; Ronald P Mensink; Andrzej Namiot; Wojciech Kisielewski; Zbigniew Namiot; Joachim Füllekrug; Robert Ehehalt; Jan F C Glatz; Maurice M A L Pelsers
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

9.  Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression.

Authors:  Dan Feng; Lena Ohlsson; Rui-Dong Duan
Journal:  Lipids Health Dis       Date:  2010-04-19       Impact factor: 3.876

10.  The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Authors:  Ivan Tancevski; Egon Demetz; Philipp Eller; Kristina Duwensee; Julia Hoefer; Christiane Heim; Ursula Stanzl; Andreas Wehinger; Kristina Auer; Regina Karer; Julia Huber; Wilfried Schgoer; Miranda Van Eck; Jonathan Vanhoutte; Catherine Fievet; Frans Stellaard; Mats Rudling; Josef R Patsch; Andreas Ritsch
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.